4.5 Article

Management of Patients With Lung Cancer and Poor Performance Status

Journal

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 12, Issue 7, Pages 1015-1025

Publisher

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2014.0098

Keywords

-

Categories

Funding

  1. Pfizer Inc.
  2. New Link Genetics, Inc.
  3. Astex Pharmaceuticals, Inc.
  4. Amgen Inc.
  5. Boehringer Ingelheim GmbH
  6. Bristol-Myers Squibb Company
  7. Veterans Health Administration

Ask authors/readers for more resources

Patients who are able to care for themselves but are unable to perform most work-related activities are considered to have a poor performance status (PS). Individuals who fulfill these criteria constitute a significant proportion of all patients with lung cancer. Patients with lung cancer and a poor PS, irrespective of age, have an increased incidence of adverse effects with therapy and poorer outcomes. Thus, although these individuals must be treated differently, data on optimal approaches for these patients are lacking, because this cohort is underrepresented in conventional clinical trials due to enrollment restrictions. This article presents the available evidence on the treatment of this group of patients with lung cancer. Although patients with PS 2 have worse overall outcomes than those with good PS, a selected proportion may still benefit from standard therapy. Further trials are needed to identify optimal strategies to treat this group of patients with lung cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available